
World-leading MRI centre
A state-of-the-art medical imaging, research and innovation centre will be built in Tairāwhiti Gisborne with $6 million from the Government’s Provincial Growth Fund and $1 million from the Eastland

A state-of-the-art medical imaging, research and innovation centre will be built in Tairāwhiti Gisborne with $6 million from the Government’s Provincial Growth Fund and $1 million from the Eastland

Ocuphire Pharma has announced late phase II clinical trials can begin on its eye drop Nyxol after receiving $5 million funding to further develop the drug.Phase I and phase II trials proved successful

A few extra few million dollars a year would dramatically cut the number of people needing cataract operations and save millions and millions of dollars helping people hurt by falls, a new Otago study


Blind Foundation changes The Blind Foundation has appointed Canadian John Mulka as its new chief executive, replacing long-term CEO Sandra Budd, who’s contract ended at the end of June. For the past

A first-of-its-kind continuous delivery system of an anti-VEGF therapy to treat wet age-related macular degeneration is a step closer now patient enrolment for a phase III clinical trial is complete.


The Royal Victorian Eye and Ear Hospital is seeking patients for a phase II clinical study of Okogen’s OKG-0301 to treat viral conjunctivitis.In partnership with the Centre for Eye Research Australia

Amazon has announced a new feature of the Alexa voice command device now allows UK users to have health queries answered by the National Health Service. A Department of Health news release said the

University of Michigan researchers have developed technology to help clinicians “see” and map patient pain in real-time, through special augmented reality (AR) glasses.Using the portable CLARAi

Phase III optical trials of teprotumumab have proved effective in the treatment of active thyroid eye disease (TED), moving the monoclonal antibody treatment closer to becoming the first approved

Medsafe has opened a public consultation on plans to introduce new labelling requirements for non-active substances in medicines that may cause allergic reactions.Group Manager Chris James said: “The
